Ví dụ về việc sử dụng Lispro trong Tiếng anh và bản dịch của chúng sang Tiếng việt
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Its active substance is insulin lispro.
Insulin lispro should be clear and colorless.
The active substance is insulin lispro.
Rapid-acting insulin(Lispro) reaches the blood within 15 minutes after injection.
Vomiting- These conditions lower blood sugar and may lower the amount of insulin orinsulin lispro you need.
Humalog is insulin lispro, a fast-acting insulin which works quickly in the bloodstream.
Each ml contains 100 units insulin lispro*(equivalent to 3.5 mg).
Always draw the insulin lispro into the syringe first, then follow with the longer-acting insulin.
The company's generic version of its Humalog U-100 isbeing sold under the chemical name insulin lispro, the Associated Press reported.
Therefore, insulin lispro should be given within 15 minutes of a meal, compared to regular insulin, which is given 30-60 minutes before meals.
With low-carbohydrate content and high-fat intake,there is an increased risk of hypoglycemia from insulin lispro within 2 hours after the meal.
Therefore, insulin lispro should be injected 15 minutes before a meal as compared to regular insulin, which is injected 30-60 minutes before a meal.
Examples of these insulins include aspart(NovoLog, Fiasp), glulisine(Apidra), lispro(Humalog, Admelog) and regular(Humulin R, Novolin R).
Fast-Acting Insulin: Insulin lispro(Humalog) and insulin aspart(Novo Rapid, Novolog) lower blood sugar very quickly, usually within 5 minutes after injection.
The objective of this study was to assess the relation between the individual insulins(glargine,aspart, lispro and human insulin) and development of breast cancer.
As compared to regular insulin, insulin lispro acts more rapidly, has an earlier maximal effect and a shorter duration action.
One of the three companies that control 90% of the world insulin market, Eli Lilly, recently did bow to public pressure byannouncing a forthcoming“authorized generic” version called Lispro.
When compared to regular insulin, insulin lispro has a more rapid onset of action, an earlier peak effect, and a shorter duration of action.
It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin( insulin medication), Humalog(insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar( insulin glargine).
Rapid-acting insulin, such as insulin lispro(Humalog) and insulin aspart(NovoLog), starts working in five to 15 minutes and peaks 30 to 90 minutes later.
Insulin lispro, sold under the brand name Humalog among others, is a type of manufactured insulin used to treat type I and type II diabetes.[1] Typically it is taken around the time of eating.[2] It is used by injection under the skin or within an insulin pump.[2][3] Onset of effects typically occurs within 30 minutes and lasts about 5 hours.[2] Often a longer acting insulin like NPH is also needed.
If you are directed to add a mixing liquid to insulin lispro before use(dilute), ask your health care professional about the correct way to dilute insulin.
Rapid-acting insulins, or regular insulin(lispro, aspart, glulisine), are given in boluses prior to meals to lower the post-meal glucose levels and to treat elevated blood glucose levels related to other causes.
For example, fast- or rapid-acting insulins, such as lispro(Humalog), glulisine(Apidra), and aspart(Novolog, Fiasp), are meant to be taken 10 to 15 minutes before eating.
In a study comparing regular insulin with insulin lispro, daily insulin doses and hemoglobin A1c levels were similar, but insulin lispro improved postprandial control, reduced hypoglycemic episodes, and improved patient convenience compared with regular insulin.
Patients who will see the biggest savings with insulin lispro who don't have health insurance, have high-deductible insurance or have Medicare Part D plans, according to Lilly.
Next, scientists began moving around amino acids to create new insulin analogs with different properties:In 1996, lispro became the first fast-acting insulin analog to be approved, with the aim of better minimizing postprandial glucose excursions, followed by aspart in 2000 and glulisine in 2004.